StreetInsider.com News Articles

Jefferies Defending Foghorn Therapeutics (FHTX) +10pct Drop: 'We view the recent pullback as a buying opportunity'

Thu, 12 Mar 2026 16:44:10 -0400

Jefferies analyst Amin Makarem reiterated a Buy rating and $12.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).

The analyst comments "FHTX plans to share the FHD-909 (SMARCA2 inhibitor) dose-expansion decision and prelim ph.I data in mid-’26 – a key near-term catalyst that could move the stock. We view the recent pullback as a buying opportunity. More granular data is likely to follow at a later med mtg. In the longer term, FHTX is advancing multiple degraders, incl EP300 in MM/DLBCL and CBP in breast cancer, with IND-enabling work in 2026 and initial data likely in 2027/28 (our est)."

For an analyst ratings

Jefferies Defending Foghorn Therapeutics (FHTX) +10pct Drop: 'We view the recent pullback as a buying opportunity'

Thu, 12 Mar 2026 16:44:10 -0400

Jefferies analyst Amin Makarem reiterated a Buy rating and $12.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).

For an analyst ratings

Foghorn Therapeutics (FHTX) Reiterated at Buy by Stifel After Q4 Results

Thu, 12 Mar 2026 07:54:23 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $12.00 price target on Foghorn Therapeutics (NASDAQ: FHTX).

The analyst commented, "On Wednesday (3/11), FHTX reported 4Q25 financial results - the company did not host a call. Net loss was $21.7M for 4Q25 and $74.3M for YE25. Management reiterated SMARCA2 Ph1 enrollment is progressing well, and dose escalation is on track. In January 2026, FHTX completed a $50M registered direct financing and appointed Ryan Maynard as CFO in February.We make no change to our Buy rating and $12 target price. Cash and cash equivalents of $158.9M as of YE25 provide runway into

Form 10-K Foghorn Therapeutics For: Dec 31

Wed, 11 Mar 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260311/26146183.html

Form 10-K Foghorn Therapeutics For: Dec 31

Wed, 11 Mar 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260311/26146183.html

Foghorn Therapeutics raises $50 million in January financing

Wed, 11 Mar 2026 16:10:44 -0400

Foghorn Therapeutics Inc. (NASDAQ: FHTX) completed a $50 million registered direct financing in January 2026 at an issue price of $6.71 per share, representing a 30% premium to the January 9, 2026 closing price, according to the company's annual report filing.

The financing included warrants covering 50% at $13.42 per share and another 50% at $20.13 per share. Investors included BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a biotech mutual fund. The company expects the funding to extend its cash runway into the first half of 2028.

As of December 31, 2025, Foghorn held $158.9 million in cash, cash equivalents

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

Wed, 11 Mar 2026 16:09:00 -0400

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)

Selective CBP degrader program with potential in ER+ breast cancer tracking to IND-enabling studies in 2026

Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)

Completed a $50 million registered direct financing in January 2026

Strong balance sheet with cash, cash equivalents, and marketable securities of $158.9 million as of December 31, 2025; with the addition of

Form 8-K Foghorn Therapeutics For: Mar 11

Wed, 11 Mar 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260311/26146114.html

Form 8-K Foghorn Therapeutics For: Mar 11

Wed, 11 Mar 2026 16:09:00 -0400
si-local-file:///var/storage/secattach/20260311/26146114.html

Form 4 Foghorn Therapeutics For: Feb 23 Filed by: Maynard Ryan D

Tue, 24 Feb 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260224/26051282.html